Loading patent…
AssigneesLudwig Institute for Cancer Research, Sloan-Kettering, Institute for Molecular Biology
InventorsGerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
Estimating the term…
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
An isolated antibody which specifically binds the extracellular region of SLC34A2.
(canceled)
(canceled)
(canceled)
An isolated immunogenic SLC34A2 polypeptide which comprises the amino acid sequence set out in any of SEQ ID NOS:
A method for screening or identifying agents or compounds which modulate SLC34A2 wherein the ability of an agent or compound to bind, interact with, or otherwise agonize or antagonize an SLC34A2 peptide selected from the group of any of SEQ ID NOS:
Dependencies are inferred from the claim text.